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Invasive bacterial diseases (meningitis, sepsis, bacter-
emic pneumonia, etc.) are a major cause of morbidity, 
and are characterized by a high fatality rate and a high 
frequency of serious and often invalidating complica-
tions [1, 2].
The symptoms of these diseases display scant specifi-
city with regard to the etiological agent. However, it is 
extremely important to know which specific agent is in-
volved, not only for therapeutic purposes and prophy-
laxis for those who come into contact with the patient, 
but also to implement primary prevention.
Glycoconjugate vaccines for the prevention of infections 
due to type b Haemophilus influenzae (Hib), types ABC 
and W135 Neisseria meningitidis (meningococcus) 
and 13 serogroups/types of Streptococcus pneumoniae 
(pneumococcus) are currently available and are effica-
cious in small children [3- 5]. It is essential to know the 
epidemiology of the diseases caused by these pathogens, 
in order to evaluate the percentage of preventable cases 
and the impact of extensive vaccination campaigns.
In 1994, a special surveillance network was set up by the 
Istituto Superiore di Sanità. The data gathered by this net-
work have provided, and continue to provide, a precise 
picture of the trends of these invasive diseases. For ex-
ample, among 1348 cases of invasive disease reported in 
2010, 851 of these were caused by S. pneumoniae, 150 by 
N. meningitidis and 70 by Haemophilus influentiae [6].
In recent years, we have been witnessing a significant 
change in the natural history in the spread of infections 
due to S. pneumoniae, thanks to the introduction of the 
heptavalent conjugate vaccine in many advanced coun-
tries. Moreover, the 13-valent conjugate vaccine has 
been available in Italy for several years, providing an 
even more effective weapon against the invasive dis-
eases caused by this pathogen, such as meningitis and 
pneumonia [5].
The monovalent conjugate vaccine against meningococ-
cus C found considerable success in those countries, such 
as the United Kingdom, where extensive vaccination cam-
paigns had been carried out [7]. Even smaller-scale strate-
gies, such as the vaccination of children at risk,13-month-
old infants and adolescents, which was introduced in Italy 
through the 2005-07 National Vaccination Plan, are be-
ginning to impact on the circulation of meningococci of 
serogroup C. This is demonstrated by the predominance 
of serogroup B among the meningococci responsible for 
invasive disease in Italy in recent years [6].
Given the resemblance between the capsular polysac-
charide of meningococcus B and human antigens, the 
research group of Novartis Vaccines and Diagnostics 
has made major efforts in the last few years to develop 
a universal vaccine for meningococcus B [8, 9]. Sup-
ported by top-level scientific research, these efforts en-
abled the elusive mechanisms with which this pathogen 
is endowed to be better understood. In particular, the 
identification of proteins which play important roles in 
the adhesion of the microorganism to the cells of the re-
spiratory tract, in its survival in the bloodstream, etc.
The goal of producing vaccines covering the vast range 
of possible invasive pathogens has gradually been 
achieved. However, further research will be necessary, 
bearing in mind the considerable adaptive capabilities 
of these potential agents of disease, for which man is the 
only natural host.
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